Paul-andre De Lame

Biography

Dr. de Lame is an intensive care medical expert with strong experience in cardiovascular medicine and infectious diseases.  He was a former executive at Merck and Warner Lambert (Pfizer) where he  focused on clinical development at Merck and Warner-Lambert (Pfizer).  He was also the co-founder and Chief Medical Officer of Cardiokine Inc. and the Chief Executive Officer of Anabase International Corp., which provides regulatory and clinical research services.  Dr. de Lame was a key contributor to many product development teams involving several vaccines and antibiotics.  He was also principally involved with the clinical development of Lipitor® (atorvastatin) and the life cycle management of imipenem/cilastatin (Tienam®, Primaxin®), gemfibrozil, quinapril (Accupril®), norfloxacin and several medical devices. Dr. de Lame received his M.D. from the Universite Catholique de Louvain, with a specialization in anesthesiology and intensive care.

Research Interest

 cardiovascular medicine and infectious diseases